**Table e-3. Demographics and clinical features of patients with confirmed COVID-19 and those without COVID-19**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Confirmed COVID-19**  **(n=5)** | **No COVID-19**  **(n = 356)** | ***p* Value** |
| **Female, n (%)** | 2 (22.2) | 239 (67.1) | 0.340 |
| **Age at survey, y, median (range)** | 52 (28-69) | 48 (20-86) | 0.690 |
| **At least 1 comorbid condition, n (%)**  **Smoking**  **Dyslipidemia**  **Diabetes**  **Hypertension**  **Heart disease**  **Pulmonary disease**  **Malignancy** | 0  0  0  0  0  0  0  0 | 167 (47.1)  65 (18.2)  78 (21.9)  24 (6.7)  54 (15.1)  8 (2.2)  17 (4.8)  8 (2.2) | 0.047  0.500  0.590  1.00  1.00  1.00  1.00  1.00 |
| **MS type, n (%)**  **RRMS**  **SPMS**  **PPMS**  **CIS** | 4 (80)  1 (20)  0  0 | 298 (83.7)  31 (8.7)  22 (6.2)  5 (1.4) | 0.780 |
| **Disease duration, y , mean (SD)** | 16.4 (8.3) | 15.4 (9.7) | 0.800 |
| **Annualized relapse rate, mean (SD)** | 0.46 (0.27) | 0.4 (0.3) | 0.560 |
| **Last EDSS score, median (range)** | 2.0 (2.0-3.0) | 2.0 (0-8.0) | 0.170 |
| **Disease modifying treatment, n (%)** | 5 (100) | 264 (74.1) | 0.330 |
| **Interferon beta**  **Glatiramer acetate**  **Dimethylumarate**  **Teriflunomide**  **Ocrelizumab**  **Rituximab**  **Natalizumab**  **Fingolimod**  **Alemtuzumab**  **Cladribine**  **Ofatumumab**  **Azathioprine**  **Ponesimod** | 1 (20)  0  1 (20)  0  0  1 (20)  1 (20)  0  0  1 (20)  0  0  0 | 60 (22.6)  35 (13.2)  50 (18.9)  30 (11.3)  10 (3.7)  17 (6.4)  14 (5.3)  34 (12.8)  4 (1.5)  5 (1.9)  2 (0.7)  1 (0.3)  2 (0.7) |  |
| **Patients who developed MS Relapse during the study period, n (%)** | 0 | 6 (1.7) | 1.00 |